Biomarkers in Multiple Myeloma

Study acronym: VESICOM
StatusActive, Not Recruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing
    • Primary completion date changed from estimate of Oct 30, 2025 to May 5, 2025
    • Eligibility criteria expanded, about 7 words
    • Site details revised at 2 of 2 sites
  2. Primary completion date: Oct 30, 2024 to Oct 30, 2025
    • Study completion date: Oct 30, 2026 to Oct 30, 2027
    v4
  3. Primary completion date: Oct 30, 2023 to Oct 30, 2024
    • Study completion date: Oct 30, 2025 to Oct 30, 2026
    v3
  4. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary completion date: Dec 15, 2025 to Oct 30, 2023
    • Start date changed from estimate of Feb 15, 2022 to May 20, 2022
    • Study completion date: Jul 15, 2026 to Oct 30, 2025
    • Site details revised at 2 of 2 sites
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The association between multiple myeloma (MM) and venous thromboembolism (VTE) is well known. Indeed, the incidence of VTE is increased in patients with newly diagnosed MM and in patients treated by immunomodulatory drugs in combination with glucocorticoids. Moreover, the clinical outcome of MM is supposed to be correlated to the risk of thrombosis. At the biological level, a number of hemostasis abnormalities participate in increasing VTE incidence. Yet, data on predictive biomarkers linked to VTE are limited.
Trial Details
NCT Number NCT05259553
Lead Sponsor Centre Hospitalier Universitaire de Saint Etienne
Conditions
(from sponsor)		 Hematological Patients, Newly Diagnosed Multiple Myeloma, Chemotherapy
Related terms Multiple Myeloma
Enrollment 70 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov